$72,141,707
to VENATORX PHARMACEUTICALS INC
VENATORX PHARMACEUTICALS: ANTIBIOTIC FOR AMR AND BIOTHREAT PATHOGENS
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Latest obligation on a 2022 antibiotic contract with VenatorX Pharmaceuticals to develop treatments for antimicrobial-resistant and biothreat pathogens.
Addresses critical gaps in antibiotic options for drug-resistant infections and potential bioweapons threats—a national security and public health priority.
Supports domestic pharmaceutical manufacturing capacity for last-resort antibiotics; reduces reliance on foreign suppliers for critical antimicrobial agents.
China dominates bulk antibiotic APIs; this contract strengthens U.S. domestic production of novel antibiotics against resistant pathogens.
Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-06-02. Cost: $0.003074.
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier CONT_AWD_75A50122C00080_7505_-NONE-_-NONE-.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.